TAGP yields 2000.00% · ABBV yields 3.06%● Live data
📍 TAGP pulled ahead of the other in Year 1
Combined, TAGP + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TAGP + ABBV for your $10,000?
Tristar Acquisition Group operates as an engineering, procurement, and construction contractor. The company, through its subsidiaries, engages in the design, fabrication, and installation of specialized equipment, known as packages or skids, and production plants for the oil and gas industry and engineering companies. It also designs, manufactures, and markets oil and gas production equipments and systems primarily for the oil and gas production separation process. The company's products and services are used for the separation of unprocessed hydrocarbon fluids into sellable oil and gas, as well as used in the production of crude oil and natural gas to separate oil, gas, and water within a production stream and to remove contaminants. Its products and services are also deployed in downstream operations, such as in refining units, pipeline, LNG liquefaction, and electric generation; and in upstream operations, including wellhead completion, collection center, the first treatment unit, and the process treatment unit. Tristar Acquisition Group installs its products on onshore facilities, as well as in offshore floating production, storage, and offloading vessels. It offers its products primarily in Belarus, Italy, Egypt and the Middle East, the United States, and internationally. Tristar Acquisition Group is headquartered in Rome, Italy.
Full TAGP Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.